Evidence map›Paper›PMID 20653937›Full record

ArticleArthritis research & therapy2010

Increased expression of costimulatory markers CD134 and CD80 on interleukin-17 producing T cells in patients with systemic lupus erythematosus.

Sebastian Dolff, Daniel Quandt, Benjamin Wilde, Thorsten Feldkamp, Fan Hua, Xin Cai, Christof Specker, Andreas Kribben, Cees G M Kallenberg, Oliver Witzke

Open access · goldAbstract read
In one paragraph

Article in Arthritis research & therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 65 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Cytokines in Systemic Lupus Erythematosus-Focus on TNF-α and IL-17.International journal of molecular sciences · 2023
    Review
  5. Article
  6. MAITabolismFrontiers in immunology · 2022
    Review
  7. Review
  8. CD107aFrontiers in medicine · 2021
    Article
  9. Review
  10. Article
  11. Article
  12. IL-22 production of effector CD4European journal of medical research · 2019
    Article
  13. Article
  14. Article
  15. Article
  16. CD4Clinical and experimental immunology · 2018
    Article
  17. Article
  18. Effects of 1,25(OH)Journal of cellular and molecular medicine · 2017
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Sebastian DolffDepartment of Nephrology, University Hospital Essen, University Duisburg-Essen, Hufelandstraße 55, Essen, Germany. Sebastian.Dolff@uk-essen.de
Daniel Quandt
Benjamin Wilde
Thorsten Feldkamp
Fan Hua
Xin Cai
Christof Specker
Andreas Kribben
Cees G M Kallenberg
Oliver Witzke
University of Duisburg-Essen · DEEssen University Hospital · DEUniversity of Groningen · NLKliniken Essen-Mitte · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere is growing evidence that interleukin 17 (IL-17) producing T cells are involved in the pathogenesis of systemic lupus erythematosus (SLE). Previous studies showed that increased percentages of T-cell subsets expressing the costimulatory molecules CD80 and CD134 are associated with disease activity and renal involvement in SLE. The aim of this study was to investigate the distribution and phenotypical characteristics of IL-17 producing T-cells in SLE, in particular in patients with lupus nephritis, with emphasis on the expression of CD80 and CD134.

methodsThirty-four patients (3 male, 31 female, mean age 41 ± 15 years) fulfilling at least four of the American College of Rheumatology (ACR) revised criteria for the diagnosis of SLE and 24 healthy controls were enrolled. T-cells from the peripheral blood were analysed by fluorescence activated cell sorting (FACS) for their expression levels of CD80, CD134 and CCR6. In vitro stimulated CD3+IL17+ cells were also investigated for the expression of these costimulatory markers. Finally, renal biopsies from SLE patients were evaluated for the presence of CD134 expressing T-cells.

resultsPercentages of IL-17 expressing T-cells were significantly increased in patients with active disease as compared to healthy controls (1.46 ± 0.58% versus 0.93 ± 0.30%, P = 0.007). The percentage of IL-17 producing T-cells was correlated with disease activity as assessed by systemic lupus erythematosus disease activity index (SLEDAI) (r = 0.53, P = 0.003). In patients, most of the IL-17 producing T-cells were confined to the CCR6+ T-cell subset (80 ± 13%). Expression of CD80 and CD134 on the IL-17 producing T-cell subset was higher in SLE than in healthy controls (HC) (CD134: 71.78 ± 14.51% versus 51.45 ± 16.58%, P = 0.002; CD80: 25.5 ± 14.99% versus 14.99 ± 5.74%, P = 0.02). Also, patients with lupus nephritis expressed higher levels of CD134+ on CD3+IL-17+ cells as compared to HC (72.69 ± 11.54% versus 51.45 ± 16.58%, P = 0.006). Furthermore, renal biopsies of lupus nephritis patients showed infiltration of CD134+ T cells.

conclusionsPercentages of IL-17 expressing T-cells correlate with disease activity. Further, these cells show increased expression of costimulatory markers such as CD134 and CD80. The presence of CD134+ T-cells in renal biopsies of lupus nephritis patients suggest that these cells migrate to the kidney and might contribute to inflammatory processes through IL-17 secretion.

Indexed as

AdultB7-1 AntigenBiomarkersBiopsyFemaleFlow CytometryHumansImmunophenotypingInterleukin-17Lupus Erythematosus, SystemicLupus NephritisMaleMiddle AgedReceptors, CCR6Receptors, OX40Severity of Illness IndexB7-1 AntigenBiomarkersCCR6 protein, humanInterleukin-17Receptors, CCR6Receptors, OX40TNFRSF4 protein, human

Identifiers

PMID20653937
PMCPMC2945048
OpenAlexW2141011841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.